Enhanced in Vivo Targeting of Site-Specific Drugs
OwnerTheodosia Maina-Nock, Berthold Artur Nock +1inventors
InventorsTheodosia Maina-Nock, Berthold Artur Nock, Marion de Jong Hendriks
Life of this patent
Estimating the term…
Abstract
The present invention relates to a compound that inhibits the activity of a degrading enzyme for use in combination with a therapeutic or diagnostic compound, preferably a moiety conjugated peptide, in the diagnosis and/or treatment of a disease, in particular cancer, to enhance targeting of the therapeutic or diagnostic compound to the disease site.
Claims40
1-40. (canceled)
A composition comprising a radiolabeled biodegradable peptide analog and a neutral endopeptidase (NEP) inhibitor,
- wherein the peptide-portion of the radiolabeled biodegradable peptide analog is a neurotensin, and
- wherein the composition is a therapeutic or diagnostic compound.
A method of diagnosing cancer, the method comprising co-administering a radiolabeled biodegradable peptide analog with a neutral endopeptidase (NEP) inhibitor,
- wherein the peptide-portion of the radiolabeled biodegradable peptide analog is a neurotensin, and
- wherein the composition is a diagnostic compound.
A method of treating cancer the method comprising co-administering a radiolabeled biodegradable peptide analog with a neutral endopeptidase (NEP) inhibitor,
- wherein the peptide-portion of the radiolabeled biodegradable peptide analog is a neurotensin, and
- wherein the composition is a therapeutic compound.
Dependencies are inferred from the claim text.